- Home
- QNCX vs VTGN Comparison
QNCX vs VTGN Comparison
Compare QNCX & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNCX | VTGN |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.2M | 28.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | QNCX | VTGN |
|---|---|---|
| Price | $3.06 | $0.68 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $7.67 | $0.90 |
| AVG Volume (30 Days) | 808.9K | ★ 6.1M |
| Earning Date | 11-12-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $721,000.00 |
| Revenue This Year | N/A | $54.26 |
| Revenue Next Year | N/A | $478.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.72 | $0.63 |
| 52 Week High | $4.55 | $5.14 |
Technical Indicators
Market Signals| Indicator | QNCX | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 23.54 |
| Support Level | $3.18 | $0.63 |
| Resistance Level | $3.80 | $0.71 |
| Average True Range (ATR) | 0.29 | 0.13 |
| MACD | -0.14 | -0.14 |
| Stochastic Oscillator | 2.01 | 1.55 |
Price Performance
Historical ComparisonAbout QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.